Effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, in isolated and perfused canine large coronary arteries.
In isolated canine epicardial coronary arteries perfused with Krebs-Henseleit solution at 37 degrees C, DN-9693, a newly synthesized selective cyclic AMP phosphodiesterase inhibitor, induced vasodilation in a dose-related manner. The threshold dose for inducing vasodilation to DN-9693 was very small, but the maximum vasodilation was not great. The order of potency for ED20 (20% dilatation) was DN-9693 greater than IBMX greater than aminophylline, but that for ED70 was IBMX greater than aminophylline greater than DN-9693, suggesting that these three PDE inhibitors have different properties.
Nakane
T
T
Department of Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan.
Chiba
S
S
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000628:Aminophylline / Q000494:pharmacology; D000818:Animals; D003331:Coronary Vessels / Q000187:drug effects* / Q000502:physiology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D011799:Quinazolines / Q000494:pharmacology*; D014664:Vasodilation / Q000187:drug effects*
D011799:Quinazolines; D000628:Aminophylline; C049662:1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3H)-one; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D015056:1-Methyl-3-isobutylxanthine